The enzymes responsible for this digestion (pepsin in the stomach, trypsin and chymotrypsin from the pancreas in the small intestine) are highly efficient and rapidly degrade most therapeutic peptides to pharmacologically inactive fragments before they can act on mucosal tissue
Ultimately, the choice depends on your needs, preferences, and circumstances
By healing the gut, and signaling the brain, it can have a profound, stabilizing effect on your mood
The precise timeline based on clinical trial tracking: Weeks 1-3: Mild symptoms beginning, most patients adapting to medication Weeks 4-8: Peak side effect period highest nausea, GI symptoms at their worst Weeks 9-12: Rapid improvement, most GI symptoms resolving Weeks 13-24: Minimal symptoms for most, discontinuation rate drops to under 2% Weeks 25-48: Essentially no side effects for 85%+, focus shifts to weight maintenance According to research published in the New England Journal of Medicine on GLP-1 agonists, this pattern is consistent across the entire class of incretin-based therapies
CagriSema (cagrilintide + semaglutide) reached 20.4% in REDEFINE 1 and 23.0% in REDEFINE 4